A new drug for Alzheimer's disease, called lecanemab, got a lot of attention earlier this year for getting fast-tracked approval based on a clinical trial that included nearly 1,800 people. It was the most diverse trial for an Alzheimer's treatment to date, but still not enough to definitively say if the drug is effective for Black people. "[In] the world's most diverse Alzheimer's trial, a giant trial of 1,800 people that lasted for a much longer time than most trials did, we're still not sure that all of the groups that are at highest risk of Alzheimer's disease actually see any kind of benefit," says Dr. Jonathan Jackson, Assistant Professor of Neurology at Harvard Medical School. On today's episode, Jonathan and Short Wave co-host Emily Kwong delve into how drug developers can overlook those hardest hit by the disease they're trying to treat.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy
No persons identified in this episode.
No transcription available yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster